ASCO

ASCO 2019 Congress

 

Expert interviews at ASCO 2019

 

Dr. Martin Reck gives an overview on where we are today regarding immunotherpaies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.

Dr Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.

Dr. Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.

Dr. Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.


ASCO 2018 Congress

English

Mandarin

Japanese

 

Expert interviews at ASCO 2018

 

Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls of liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Terufumi Kato talks about the nationwide screening project LC-SCRUM-Japan and the insights that have been obtained through these data in general and regarding squamous-cell lung cancer in particular.

 


ASCO 2017

Expert interviews at ASCO

 

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options

 


ASCO 2016

English

Spanish

Mandarin

 


ASCO 2015